Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Reply to left atrial strain: A potential target to predict atrial fibrillation

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Coronary artery- and aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Predictive value of left atrial strain in relation to atrial fibrillation following acute myocardial infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Refractory in-hospital cardiac arrest - no time to waste

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  1. Recurrent syncope in patients with a pacemaker and bradyarrhythmia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-term effects of cardiac rehabilitation after heart valve surgery - results from the randomised CopenHeartVR trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Symptoms reported in calls to emergency medical services within 24 hours prior to out-of-hospital cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: To compare effectiveness and safety of clopidogrel, prasugrel, and ticagrelor among all-comers with ST-segment elevation myocardial infarction (STEMI) and extend the knowledge from randomized clinical trials.

METHODS: All consecutive patients with STEMI admitted to Copenhagen University Hospital, Rigshospitalet, from 2009 to 2016 were identified via the Eastern Danish Heart Registry. By individual linkage to Danish nationwide registries, claimed drugs and end points were obtained. Patients alive a week post-discharge were included, stratified according to clopidogrel, prasugrel, or ticagrelor treatment, and followed for a year. The effectiveness end point (a composite of all-cause mortality, recurrent myocardial infarction, and ischemic stroke) and safety end point (a composite of bleedings leading to hospitalization) were assessed by multivariate Cox proportional-hazards models.

RESULTS: In total, 5123 patients were included (clopidogrel [1245], prasugrel [1902], ticagrelor [1976]) with ≥95% treatment persistency. Concomitant use of aspirin was ≥95%. Females accounted for 24% and elderly for 17%. Compared with clopidogrel, the effectiveness end point occurred less often for ticagrelor (HR 0.50, 95% CI 0.35-0.70) and prasugrel (HR 0.48, 95% CI 0.33-0.68) without differences in bleedings leading to hospitalization. No differences in comparative effectiveness or safety were found between prasugrel and ticagrelor. Sensitivity analyses with time-dependent drug exposure and the period 2011-2015 showed similar results.

CONCLUSIONS: Among all-comers with STEMI, ticagrelor and prasugrel were associated with reduced incidence of the composite end point of all-cause mortality, recurrent myocardial infarction, and ischemic stroke without an increase in bleedings leading to hospitalization compared with clopidogrel. No differences were found between prasugrel and ticagrelor.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cardiology
Vol/bind342
Sider (fra-til)15-22
Antal sider8
ISSN0167-5273
DOI
StatusUdgivet - 1 nov. 2021

Bibliografisk note

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

ID: 67986679